Gary S. Gillheeney - 26 May 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
President and CEO, Director
Signature
/s/ William R. Kolb, Attorney-in-Fact
Issuer symbol
ORGO
Transactions as of
26 May 2022
Net transactions value
-$1,079,637
Form type
4
Filing time
31 May 2022, 17:16:49 UTC
Previous filing
25 May 2022
Next filing
03 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Options Exercise $60,590 +61,202 +15% $0.9900 459,444 26 May 2022 Direct
transaction ORGO Class A Common Stock Sale $349,463 -61,202 -13% $5.71 398,242 26 May 2022 Direct F1, F2
transaction ORGO Class A Common Stock Options Exercise $55,798 +56,362 +14% $0.9900 454,604 27 May 2022 Direct
transaction ORGO Class A Common Stock Sale $334,227 -56,362 -12% $5.93 398,242 27 May 2022 Direct F1, F3
transaction ORGO Class A Common Stock Options Exercise $108,148 +109,240 +27% $0.9900 507,482 31 May 2022 Direct
transaction ORGO Class A Common Stock Sale $620,483 -109,240 -22% $5.68 398,242 31 May 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -61,202 -13% $0.000000 412,936 26 May 2022 Class A Common Stock 61,202 $0.9900 Direct F5
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -56,362 -14% $0.000000 356,574 27 May 2022 Class A Common Stock 56,362 $0.9900 Direct F5
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -109,240 -31% $0.000000 247,334 31 May 2022 Class A Common Stock 109,240 $0.9900 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $5.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.89, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 100% of the shares subject to the option are fully vested and exercisable.